Research yields pricey chemicals from biodi...(value products. Technologies based ...)
Navigation Links
Research yields pricey chemicals from biodiesel waste
Date:6/30/2008
value products."
Technologies based on Gonzalez's work have been licensed to Glycos Biotechnologies Inc., a Houston-based startup company that plans to open its first demonstration facility within the next 12 months.
'/>"/>
| Contact: Jade Boyd jadeboyd@rice.edu 713-348-6778 Rice University Source:Eurekalert |
Related biology news :
1. Montreal Heart Institute and Mount Sinai Hospital researchers contribute to Crohns disease study
2. Salk researchers reprogram adult stem cells in their natural environment
3. UIC researchers make promising finding in severe lung disease
4. Montana State researchers release guide to noninvasive carnivore research
5. Growth hormones link to starvation may be clue to increasing life span, researchers find
6. Impact Factor names Cell top research journal
7. Research required urgently to control planthopper pests
8. Researchers explain nitrogen paradox in forests
9. UC Davis researcher leads climate-change discovery
10. New grants will support research in the sustainable built environment
11. UNH researchers test sediment-scrubbing technology in NH river
Post Your Comments:
Breaking Biology News(10 mins):Introns: A mystery renewed 2Introns: A mystery renewed 3Introns: A mystery renewed 4 Killer catfish? Venomous species surprisingly common, study finds 2Climate projections underestimate CO2 impact 2New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements 13732 1New Generation Biofuels Receives NASDAQ Notice of Noncompliance with Continued Listing Requirements 13732 2Study Details Swine Flu Transmission Rates 55637 1Study Details Swine Flu Transmission Rates 55637 2Study Details Swine Flu Transmission Rates 55637 3New tool to predict the risk of death in COPD may help physicians to individualize treatment 55633 1New tool to predict the risk of death in COPD may help physicians to individualize treatment 55633 2
Other Biology News:Language of a fly proves surprising 2Language of a fly proves surprising 3Typical North American diet is deficient in omega-3 fatty acids 2Wandering albatrosses follow their nose 2
Breaking Biology Technology:Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
[0] Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer[0] Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology[0] Successful Stem Cell Therapy for Treatment of Eye Disease[0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
Other Biology Technology:Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |